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Results. The most frequent keloid site was ear lobe (n: 10). Three cases were lost and excluded during the follow up. Response to
therapy was shown in 13 cases (76.5%).
Complete response. 9 (53%), Hypertrophic scars: 4, and relapses: 4 (23.5%, mean time: 1 year). After 2 years of follow up, 12 cases
continued as responders (90.3%), 9 cases (69.3%) after 3 years and after 4 years, 8 (61.5%) are still in response. Consequences were
pain and pruritus in 5 patients (29.4%).
Conclusion. Post-excision radiotherapy seems to be an optimum technique in handling keloids. However, electron therapy using
a spoiler needs to be further evaluated in practice. Our results seem to be similar to those obtained with other techniques, such
a Brachytherapy or superﬁcial X-ray.
http://dx.doi.org/10.1016/j.rpor.2013.03.608
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Introduction. Volumetric Modulated Arc Therapy is the last generation of arch dynamic therapy, a technology that allows better
dose conformation, signiﬁcant reduction of treatment time, improvement of patient comfort, reduce the risk of patientmovement
during treatment and reduce the dose received by the organs at risk.
Objective. The purpose of this paper is to present the case of a bilateral ductal invasive carcinoma treated with adjuvant radio-
therapy using VMAT in order to demonstrate its dosimetric advantages.
Materials and methods. The patient is a 62 year old woman diagnosed in April 2011 with Bilateral Ductal Invasive Breast Carcinoma,
cT4 cN1 M0 (Stage IIIB). The patient receives neoadjuvant chemotherapy (Adriamicine-Ciclofosfamide×4, followed by weekly
Paclitaxel×12), followed by a bilateral radical mastectomy and axillary lymph node resection. After that, the woman was sent
to our department to receive adjuvant radiotherapy. Given the characteristics of the target volume, radiotherapy planning with
VMAT technique was chosen in order to reduce the dose received by the organs at risk.
Results. Our PTV was both chest walls and bilateral axillary and supraclavicular lymph node chains. The total dose was 50Gy
delivered in 25 fractions with a daily dose of 200 cGy. Planning was carried out using Monaco 2.03 with an full arch, 154 segments
and 737.24 monitor units. In ﬁgure 1 shows the Dose-Volume histogram, the isodoses in an axial, coronal and 3D reconstruction
and the isodose of 20Gy. Table 1 shows the mean dose to the PTVs and the organs at risk. PTV right chest wall (Doses mean
“Dm”: 50.80Gy); PTV left chest wall (Dm: 51.06Gy); PTV right node (Dm: 50.68Gy); PTV left node (Dm: 50.78Gy) and mean dose in
the most important organs at risk: Heart, (Dm: 12.94Gy and V20: 17.82Gy); right lung, (Dm: 11.96Gy and V20: 18.75Gy) and left
lung, (Dm: 12.08Gy and V20: 19.33Gy). Treatment was carried out using an Elekta Synergy linear accelerator.
Conclusion. Using VMAT, we can administer our planned dose to large PTVs (in this case both chest walls, axillary and supracla-
vicular chains) and exclude organs at risk (heart and lungs) from the dose of 20Gy.
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Introduction.Weknowobjectivewaysof determining the locationof the radiotherapy treatment isocenter (Image-GuidedRadiation
Therapy), but in many hospitals this is done through portal imaging (2D–2D) supervised by specialists. Without the aid of these
technological means, we can question the inﬂuence exerted by the specialists’ subjectivity on the correct placement of the
isocenter.
Objectives. Observe whether there is a signiﬁcant inﬂuence on the coordinate shifts performed by different specialists for different
tumor sites.
Methods. We studied 552 patients treated with a Siemens Primus linear accelerator. The corrections performed on the treatment
isocenter were analyzed in relation to the position established in the planning stage. These corrections may vary in subsequent
days of treatment giving us a history of not only the variability inherent to the conditions of the patients but also of the variability
due to the degree of subjectivity of the radiation oncologist. Corrections were made based on the realization of portal imaging
tests within the ﬁrst three days of treatment, and then on a weekly basis. We calculated corrections in each of the Cartesian axes
(Dx, Dy and Dz) made for each patient. We also analyzed the maximum coordinate shifts. After grouping patients by pathology
and radiation oncologist, we performed a statistical analysis to test for signiﬁcant differences among different specialists in
determining the isocenter.
